The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?

Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?

June 8, 2017 • By Marilynn Larkin

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn’t have dangerous side effects, researchers say.

You Might Also Like
  • Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA
  • New Research Shows Chondroitin Sulphate Reduces Cartilage Volume Loss, Bone Marrow Lesions
  • Hip Exercises May Improve Walking, Pain with Knee Arthritis

Dr. Jean-Yves Reginster of Liege State University in Belgium and colleagues recruited 604 people over age 50 with knee osteoarthritis (OA) from five European countries and randomly assigned them to take 800 mg extra-pure chondroitin sulfate (Chondrosulf), 200 mg celecoxib or a placebo every day for six months.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Those who took chondroitin sulfate or celecoxib had similar levels of pain relief at the end of the study, and in both groups the improvement was greater than for those taking just a placebo, according to the report May 22 online in Annals of the Rheumatic Diseases.1

Reginster tells Reuters Health the findings are in line with earlier studies showing pharmaceutical-grade chondroitin sulfate could significantly decrease the progression of knee OA over a period of three years.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He stressed that pharmaceutical-grade chondroitin is not the same as over-the-counter supplements, which are made differently and can’t get into the joint in high enough concentrations to combat the causes of cartilage degradation and pain.

European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate, as well as pharmaceutical-grade glucosamine sulfate, as first-line treatments for OA, Reginster says by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs), including stomach ulcers, bleeding, liver and kidney problems.

Dr. Michael Shepard of Hoag Orthopedic Institute in Orange, Calif., noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In addition, U.S.-based studies of chondroitin have had mixed results, says Shepard, who wasn’t involved in the study. Some have found the supplements to be as effective as ibuprofen (also an NSAID), and some have found that chondroitin sulfate is no more effective than placebo, he tells Reuters Health.

“I tell my patients, ‘buyer beware,’” Dr. Shepard say. “I tell them about the mixed results of chondroitin in the literature. I tell them to try chondroitin for one month as a trial and if they like it and feel better with it, then keep taking it.”

If chondroitin doesn’t work for them, he suggests taking an NSAID periodically, and to be aware of the side effects.

“If you are going to stay on an NSAID for a prolonged period then you need regular follow up with your doctor,” Shepard cautions.

Pages: 1 2 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: chondroitin sulfate, Knee Osteoarthritis (OA), knee pain, nonsteroidal antiinflammatory drug (NSAID), NSAIDs, Pain

You Might Also Like:
  • Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA
  • New Research Shows Chondroitin Sulphate Reduces Cartilage Volume Loss, Bone Marrow Lesions
  • Hip Exercises May Improve Walking, Pain with Knee Arthritis
  • Larger Weight Loss Tied to Greater Improvements in Arthritic Knees

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.